# Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection

> **NCT03074331** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 130 (actual)

## Conditions studied

- Hepatitis C Virus Infection

## Interventions

- **DRUG:** SOF/VEL

## Key facts

- **NCT ID:** NCT03074331
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-23
- **Primary completion:** 2018-02-07
- **Final completion:** 2018-02-07
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2019-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03074331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03074331, "Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03074331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*